5 big biotech losers from JPMorgan's massive healthcare conference

Ticker: ALDR

Share drop: -8.2% on January 8

What happened: Alder is working on a type of migraine-prevention drug known as a CGRP inhibitor. The company presented at the JPMorgan conference on January 8. You can see the company's presentation here.

Ticker: DOVA

Share drop: -10% on January 8

What happened: Dova sells a treatment for the blood disease known as thrombocytopenia. The company presented at the J.P. Morgan Healthcare Conference on January 8, and discussed additional potential markets for its treament. You can see the presentation here.

Ticker: CRNX

Share drop: -7.1% on January 10

What happened: Crinetics is working on treatments for endocrine diseases and tumors. The company presented at the J.P. Morgan Healthcare Conference on January 9, after the close of regular trading. You can see Crinetics's slides from the event here.

Ticker: RUBY

Share drop: Rubius lost 8.1% on January 7, and another 8.6% on January 8.

What happened: Rubius presented at the J.P. Morgan Healthcare Conference on January 7, and provided an update on its 2019 plans. You can see the slides from the company's presentation here.

Ticker: SGMO

Share drop: -14% on Wednesday, January 9.

What happened: Sangamo tumbled on the day it presented at the J.P. Morgan Healthcare Conference. The company aims to use gene therapies to treat diseases like hemophilia and sickle cell. It told investors to expect some updates on two trials of treatments for metabolic diseases in February, but that other info on the trials won't be available at that time.

You can see the company's slide presentation here.